2017

The Role of Kinase Fusion DNAJB1-PRKACA in Fibrolamellar Hepatocellular Carcinoma

Yi Guo
Mayo Clinic, guo.yi@mayo.edu

Follow this and additional works at: http://scholarscompass.vcu.edu/hepa_cancers

Part of the Cancer Biology Commons, and the Medicine and Health Sciences Commons

© The Author(s)

Downloaded from
http://scholarscompass.vcu.edu/hepa_cancers/5

This Abstract Accepted for Presentation is brought to you for free and open access by the Dept. of Pathology at VCU Scholars Compass. It has been accepted for inclusion in Hepatobiliary Cancers: Pathobiology and Translational Advances by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
The Role of Kinase Fusion DNAJB1-PRKACA in Fibrolamellar Hepatocellular Carcinoma

Cassandra A. Kersten¹, Bing Shui¹, Robert J. Plummer¹, Lixia Guo², Angela Gregor¹, Kenneth C. Uy¹, Yanan Yang¹,², Michael S. Torbenson³, Ying Peng¹, and Yi Guo¹,⁴

¹Department of Biochemistry and Molecular Biology,
²Division of Pulmonary and Critical Care Medicine,
³Division of Laboratory Medicine and Pathology,
⁴Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA

Background: Kinase fusion has been detected in a variety of cancer types. Approximately 3% of cancers are associated with different kinase fusions, including fibrolamellar hepatocellular carcinoma (FLC). FLC is a rare type of liver cancer that predominantly occurs in teenage population without any previous liver disease history. It is aggressive and currently surgical resection remains the only effective therapeutics. DNAJB1-PRKACA fusion is detected in at least 80% of FLC cases and is considered a potential oncogenic factor. However, the causality between DNAJB1-PRKACA fusion and FLC is not yet established.

Methods: This study aims at investigating the function of DNAJB1-PRKACA fusion in FLC oncogenesis using Drosophila and murine in vivo models. We used the Gal4/UAS system to overexpress human DNAJB1-PRKACA fusion gene in Drosophila eyes and used genetic and pharmaceutical inhibition of PKA activity to rescue the eye phenotype. We also used CRISPR/Cas9 genome engineering to recreate the murine chromosomal deletion equivalent to that found in FLC patients. gRNAs were designed to target murine DNAJB1 and PRKACA introns and tested for their editing efficiency. Co-transfection of a pair of effective gRNAs successfully generated a 360kb chromosomal deletion on chromosome 8 in murine hepatocytes. Multiple single cell clones were isolated, first characterized for their in vitro proliferation properties, and further inoculated subcutaneously in vivo to monitor their oncogenicity.

Results: Human DNAJB1-PRKACA fusion gene, when expressed in Drosophila eye progenitor cells, induced proliferation and differentiation phenotypes, including decreased eye size and abnormal eye shape. Both genetic and pharmaceutical inhibition of PKA activity rescued the fly eye phenotype. Murine hepatocyte cell lines carrying endogenous DNAJB1-PRKACA fusion gene have higher PKA activity like in FLC patients. These engineered hepatocytes formed subcutaneous tumors at faster rate in vivo and significantly promoted ductular metaplasia tumors.

Conclusion: DNAJB1-PRKACA fusion gene expression alone is sufficient to perturb cell growth and differentiation in different cellular contexts. In vivo modeling with engineered murine hepatocytes recapitulates certain prominent aspects of FLC pathological features, confirming its proposed role as a driver oncogene for FLC. Our Drosophila FLC model is ready as a medium throughput platform for FLC therapeutic screens.